IONIS PHARMACEUTICALS INC(NASDAQ:IONS) stock News

IONS Latest News, Press Relases and Analysis

All

Press Releases

3 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen Provides Regulatory Update on High Dose Regimen of Nusinersen

4 days ago - By: Stocktwits - Mentions: EAOR PBE

Ionis Pharma Stock Rises After Multiple Price Target Hikes On Heels Of Positive Study Results In Alexander Disease

4 days ago - By: Benzinga

What Analysts Are Saying About Ionis Pharmaceuticals Stock

5 days ago - By: Benzinga

Ionis Pharmaceuticals Reveals 'Unprecedented Results' From Rare Neurological Disease Trial

5 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis announces positive topline results from pivotal study of zilganersen in Alexander disease

8 days ago - By: Ionis Pharmaceuticals, Inc.

TRYNGOLZA® (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)

9 days ago - By: Biogen Inc. - Mentions: BIIB

Biogen to Acquire Alcyone Therapeutics, Expanding Drug Delivery Solution Portfolio for Key Product and Pipeline Candidates

15 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis expands Surf Away+ event, marking 10 years of creating unique adaptive experiences for people with neurological diseases

a month ago - By: Stocktwits

Retail Traders Pile Into Ionis As Wall Street Hikes Price Targets On FDA Approval Of Swelling Disorder Therapy

17 days ago - By: Zacks Investment Research - Mentions: RARE ADPT AKRO

IONS Up on FDA's Breakthrough Tag for ION582 in Angelman Syndrome

18 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis receives U.S. FDA Breakthrough Therapy designation for ION582 in Angelman syndrome

18 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis to host investors and analysts for Innovation Day 2025

24 days ago - By: Yahoo Finance

Ionis Pharma (IONS) Touches New High on Promising Olezarsen Results

2 months ago - By: The Motley Fool

Ionis (IONS) Q2 Revenue Soars 101%

24 days ago - By: Zacks Investment Research - Mentions: AZN GSK BIIB

IONS Hits 52-Week High on Tryngolza's Success in Lowering Triglyceride

24 days ago - By: Ionis Pharmaceuticals, Inc.

Ionis to present at upcoming investor conferences

25 days ago - By: Stocktwits - Mentions: EAOR AVSU

IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies

25 days ago - By: Investor's Business Daily

Ionis Pharma Hits The 'Bull Case,' 'Blue Sky' In Lowering Triglycerides. Shares Launch.

25 days ago - By: Ionis Pharmaceuticals, Inc.

Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG)

a month ago - By: Yahoo Finance - Mentions: JPM

J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating

a month ago - By: Ionis Pharmaceuticals, Inc.

DAWNZERA™ (donidalorsen) approved in the U.S. as first and only RNA-targeted prophylactic treatment for hereditary angioedema

2 months ago - By: Yahoo Finance - Mentions: MS NVDA

Why Morgan Stanley Upgraded This Biotech Stock to a Buy